Connecticut’s attorney general announced October 9 that the state joined a federal and multistate civil settlement with Takeda Pharmaceuticals, U.S.A., Inc., over alleged improper payments connected to prescribing Trintellix.
The office says Takeda paid $13,670,921 plus accrued interest. Of that amount, $1,703,572 is allocated to participating states’ Medicaid programs, including $213,674 attributable to Connecticut.
The allegations concern January 2014 through October 2020. Authorities contend that speaker payments and meals were used to induce prescriptions and caused false claims to publicly funded healthcare programs.
The resolution is a civil settlement of allegations, not a criminal conviction or a finding about the drug’s clinical effectiveness. The announcement does not identify a particular Eastern Connecticut provider.
This account relies on the attorney general’s public release. The stated Connecticut share is an allocation within the settlement; it is not described as a direct payment available to individual patients.